about
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient RegistryHospital volume and the outcomes of mechanical ventilationPredictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007.Factors associated with mortality in patients with tuberculosisInhaled antibiotics for lower airway infections.Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia.An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine.Update in cystic fibrosis 2012.Out-of-hospital fluid in severe sepsis: effect on early resuscitation in the emergency department.Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbationInfluenza-associated cystic fibrosis pulmonary exacerbations.Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu TrendsOut-of-hospital characteristics and care of patients with severe sepsis: a cohort studyHighly effective cystic fibrosis clinical research teams: critical success factors.Pulmonary function in the morbidly obese.Influenza pneumonia surveillance among hospitalized adults may underestimate the burden of severe influenza disease.The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011Risk factors for chronic kidney disease in adults with cystic fibrosis.Correction: Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011.Nature and correlates of post-traumatic stress symptomatology in lung transplant recipients.Update on cystic fibrosis epidemiology.Tackling the increasing complexity of CF care.Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis.The burden of influenza-associated critical illness hospitalizationsChange in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States.Clinical trial participants compared with nonparticipants in cystic fibrosis.It Starts at the Beginning: Effect of Particulate Matter In Utero.Aggressive prenatal care results in successful fetal outcomes in CF women.Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United StatesChildren and young adults with CF in the USA have better lung function compared with the UK.Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgeryCystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohortsNature versus Nurture: Does Genetic Ancestry Alter the Effect of Air Pollution in Children with Asthma?Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.Management of comorbidities in older patients with cystic fibrosis.
P50
Q22305306-967F1F45-6AB6-4635-888B-BCEF497215AEQ28250595-A7745514-2888-45D2-A003-CF86A3846406Q30389549-8416B958-0ECD-4899-BB9A-3FDEEE4B1736Q30988371-0F2CFE62-50E0-466B-8B15-ED6A9DC593A5Q33640488-D74092D5-85F4-4F7F-8205-B5EDC00FEA1CQ33714479-A085E3D5-E3BF-4277-8C3F-8B73A5CACBECQ33735726-E485DB81-4995-4862-B56E-E933A818B98EQ33738510-0BDFB001-B7B1-44DD-9D49-359123A11B19Q33740573-5FF86CE6-F48E-48ED-A7EF-571D9F66B1E8Q33744911-01844327-6966-49CC-B9F9-038B2EB9F1D7Q33776832-05486FC3-B49E-415C-9E68-AD4022F59A65Q33893785-56B2B46B-C7A6-42C4-9E81-5EAEE450951BQ33996484-251CE158-3A39-40DB-840A-33A126824817Q34011887-91F75C03-E9CF-4821-897C-2AD45CC73784Q34247972-5F5477A9-D27F-49DD-ABB4-109CEA739C63Q34572169-7F9BEF70-5BE5-4A80-81BF-6EB77A140B6DQ35012439-DEACE2CF-80C6-4285-AA6A-50DDC902FC54Q35536357-91001D90-C924-4D77-85CA-B7A0CA3D9BDDQ35667562-07D61D64-B694-4686-9267-AEE49FE546F3Q35682983-BFAC86B5-A30A-4E06-A90E-CB5C2F096CF2Q35801718-75C1D6B9-B5E9-4039-88F2-03D56D5A5A80Q35842978-6A7CFEEC-B50B-4367-B95D-41ED4E5D5A8BQ35930617-27E3B8E1-60D9-459B-A6AE-DA447BF72C85Q36034488-1365E647-5B5E-4238-9DD6-63A6AB00F96AQ36163519-8CDC8CA2-71DE-47B0-8A00-D86CA5DF074CQ36204702-2C3C9F98-0F66-49A4-9C16-730CF168B9DBQ36215326-84C36A1B-613A-4FEC-9B82-C1D876BAAF55Q36254493-B7AA4747-D437-4231-B97C-0841938BEC30Q36271493-94E3CC88-5C98-4F40-A45C-EF1117EB4630Q36272415-7F839156-EE61-49D3-8387-E900501313F1Q36464838-8A1242E7-9D82-46CC-B76D-EC6F81D590CFQ36652904-563B6BC4-ACC8-4BC4-AB79-ACB269F25F90Q36788805-DA0B21AA-B94F-4A5B-8434-401ED74BF0D9Q36818364-872F3E6B-0DC1-4C0E-9361-EF5709F12C89Q36889990-5EA84F61-D794-4B63-9F6E-C6C8508AA80FQ36924692-06CF7D6C-3C29-40E9-94B1-6B6C25004A06Q36957531-49807D9F-B91D-43C4-8A9C-5B774C52E1A4Q37013215-C1850012-364F-4304-A889-DA87FC209622Q37628124-8EB0ACB4-565C-488C-867E-C46039C2437EQ38178773-CD983C67-C319-4EDB-A637-CED300BCE47F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher H Goss
@ast
Christopher H Goss
@en
Christopher H Goss
@es
Christopher H Goss
@nl
Christopher H Goss
@sl
type
label
Christopher H Goss
@ast
Christopher H Goss
@en
Christopher H Goss
@es
Christopher H Goss
@nl
Christopher H Goss
@sl
prefLabel
Christopher H Goss
@ast
Christopher H Goss
@en
Christopher H Goss
@es
Christopher H Goss
@nl
Christopher H Goss
@sl
P106
P21
P31
P496
0000-0001-8602-0309